Viking Therapeutics, Inc. financial data

Symbol
VKTX on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 11 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2040% % -40%
Debt-to-equity 5.2% % 66%
Return On Equity -48% % -298%
Return On Assets -46% % -290%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 115,554,295 shares 2.9%
Common Stock, Shares, Outstanding 114,793,067 shares 2.9%
Entity Public Float $2,976,737,289 USD -26%
Common Stock, Value, Issued $1,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 112,667,303 shares 3.3%
Weighted Average Number of Shares Outstanding, Diluted 112,667,303 shares 3.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $344,955,000 USD 239%
General and Administrative Expense $48,387,000 USD -1.8%
Operating Income (Loss) $393,342,000 USD -161%
Net Income (Loss) Attributable to Parent $359,639,000 USD -227%
Earnings Per Share, Basic -3.19 USD/shares -216%
Earnings Per Share, Diluted -3.19 USD/shares -216%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $165,810,000 USD 522%
Assets, Current $715,598,000 USD -21%
Operating Lease, Right-of-Use Asset $85,000 USD -92%
Assets $715,729,000 USD -21%
Accounts Payable, Current $53,251,000 USD 443%
Liabilities, Current $76,667,000 USD 180%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $76,667,000 USD 173%
Retained Earnings (Accumulated Deficit) $847,546,000 USD -74%
Stockholders' Equity Attributable to Parent $639,062,000 USD -27%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $639,062,000 USD -27%
Liabilities and Equity $715,729,000 USD -21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $52,331,000 USD -753%
Net Cash Provided by (Used in) Financing Activities $349,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $63,245,000 USD
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 114,793,067 shares 2.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance $264,737,000 USD 61%
Deferred Tax Assets, Gross $264,984,000 USD 61%
Operating Lease, Liability $137,000 USD -88%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $358,473,000 USD -225%
Operating Lease, Liability, Current $137,000 USD -72%
Operating Lease, Weighted Average Discount Rate, Percent 0.0628 pure 72%
Deferred Tax Assets, Operating Loss Carryforwards $68,178,000 USD 67%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $247,000 USD -12%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%